Skip to main content
. Author manuscript; available in PMC: 2010 Jan 29.
Published in final edited form as: J Invest Dermatol. 2009 Apr 2;129(9):2156. doi: 10.1038/jid.2009.61

Figure 6. Majority of anti-desmoglein 1 (Dsg1) antibody binding in PF and PV sera targets the mature form more than the precursor form of Dsg1.

Figure 6

(a) Coomassie blue staining of purified recombinant baculoproteins used for precursor and mature Dsg1 ELISA plates. White arrowhead indicates the precursor form and black arrowhead indicates the mature form. (b) Binding curves of representative anti-Dsg1 scFv antibodies (3–30/3h, 3–97/1c, 1–18/L12) and control scFv (AM3–13) against mature and precursor Dsg1 ELISA plate. (c) Dispersion of immunoreactivity of 45 PF sera between the mature and precursor Dsg1 ELISA plate. Each closed square represents single patient. Note that most PF sera had stronger reactivity against mature Dsg1 plate than precursor Dsg1 plate. (d) Dispersion of immunoreactivity of 20 mucocutaneous PV sera between the mature and precursor Dsg1 ELISA plate. Each closed triangle represents single patient. Similar to PF patients, most PV sera had stronger reactivity against mature Dsg1 plate than against precursor Dsg1 plate.